Headache in Medical Technology
Navigation Links
Headache in Medical Technology
... (3.4 percent), hypotension (2.2 percent), and/or headache (1.1 percent).
High blood pressure can cause ... respiratory tract infection (4 patients, 2.2%), headache (4 patients, 2.2%), and hypotension (4 patients, 2.2%). Among individual treatment regimens, headache (4 patients, 2.4%) and dizziness (4 patients, ...
... 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the ... 1%, 1%; vomiting <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; constipation 1%, 0%; convulsions 3%, 3%; ... were: nausea 10%, 53%; vomiting 6%, 42%; headache 6%, 41%; fatigue 4%, 34%; constipation 1%, 33%; ...
... presented in poster presentations at the European headache and Migraine Trust International Congress 2008 in ... was headache response, defined as a reduction in headache severity from moderate to severe at baseline to mild or no headache at two hours after initiation of infusion of ...
... 50th Annual Scientific Meeting of the American headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead ... in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence ...
... therapy. He is a member of the American headache Society, The International headache Society and The National headache Foundation. Dr. Goldstein is a Board ...
... loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American headache Society, which being held at the Marriott ... Loxapine, a Dopamine Antagonist, Reduces headache Pain in Patients Having an Acute Migraine ...
... of neurology and director of the Jefferson headache Center at Thomas Jefferson University and an ... are undiagnosed. According to the International headache Society's diagnostic criteria, migraine is ... only be used where a clear diagnosis of migraine headache has been established. Treximet may cause an ...
... onset of a migraine and were treated once their headache was considered to be of moderate or severe ... in the placebo dose group. Patients rated their headache pain using the International Headache Society ... Migraine Headaches According to the National headache Foundation, approximately 13 million people in ...
... The primary efficacy endpoint for the trial is headache pain relief at two hours post-dose. ... and sustained pain free at 24 hours, and headache recurrence and relapse. Additional measures ... in the U.S. suffer from migraines. In addition to headache pain, migraine attacks are frequently accompanied ...
... 2 hours post-dose, using the standard 4-point rating scale (International headache Society). Secondary efficacy endpoints for the trial include pain relief ... About Acute Migraine Headaches According to the National headache Foundation, approximately 13 million people in the United States have been ...
... anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... of patients, with most mild to moderate in severity. The most common were headache (34 percent), contusion (32 percent), and fatigue (31 percent). ... General Safety -- In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction, occurring in 35 ...
... anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... (>10%) were rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%) and vomiting (21%). The most ... (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased ...
... adverse events seen with Focalin XR were dyspepsia, decreased appetite, headache and anxiety in pediatric studies; and dry mouth, dyspepsia, feeling jittery, dizziness, headache and anxiety in adult studies. Focalin XR is contraindicated in patients ...
... ACTEMRA arm of the AMBITION trial were upper respiratory tract infections, headache and nasopharyngitis. About RADIATE Study The RADIATE (RheumAtoiD ... clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were ...
... were upper respiratory tract infections, nasopharyngitis, hypertension, headache and an increase in transaminases. "At one year, the results from the ... clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were ...
... As reported last October, tezampanel met its primary endpoint of headache pain relief in a double-blind, placebo-controlled, Phase IIb trial ... opportunities for tezampanel and NGX426 as treatments for migraine headache and other chronic pain and non-pain indications. This will be in addition ...
... to be drug-related were application site reactions, nausea, headache and dizziness SP 792 * In a multi-center, double-blind, ... adverse events were application site reactions (27.2%), nausea (21.5%), headache (17.6%) and somnolence (12.6%) 24-Month, Open-Label Extension Trial in ...
... usually transient and mild to moderate in severity.(1,2) Treatment-related adverse events greater than 10 percent included somnolence (32 percent), headache (26 percent), fatigue (18 percent), upper abdominal pain (14 percent), and sedation (13 percent).(11) Small to modest changes in blood pressure, ...
... A dry, irritated eye with tears dripping from the corner Pain around the ear or jaw, ringing in the ears, sensitivity to noise headache Loss of taste or a decrease in saliva production Bell's palsy can affect anyone, at any age. The risk rises until about age 40 ...
... tolerated. The adverse events reported most frequently in the ACTEMRA arms of the studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. About the AMBITION Study AMBITION, a two-arm, randomized, double-blind, placebo-controlled study, was designed to ...
... the SF-36 health survey and for all sections of the EQ-5D questionnaire(6). The most commonly reported adverse events for tadalafil 40 mg were headache (42 percent for tadalafil 40 mg, versus 15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus 4 percent with placebo) and ...
... adverse events (reported frequency greater than or equal to 10% among lurasidone subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% ...
... with HZT-501 was well-tolerated. The most commonly reported adverse events in these two studies were dyspepsia, nausea, diarrhea, constipation, headache and upper respiratory tract infection. The majority were mild to moderate in severity. There were no significant differences in adverse event or ...
... moderate in severity. In clinical trials (N=535), the most common treatment-related adverse events with Lialda 2.4 g/day, 4.8 g/day and placebo were headache (5.6%, 3.4% and 0.6%, respectively) and flatulence (4%, 2.8% and 2.8%, respectively). Pancreatitis occurred in less than 1% of patients during ...
... were usually transient and mild or moderate in severity. Treatment-related adverse events greater than 10 percent included somnolence (32 percent), headache (26 percent), fatigue (18 percent), upper abdominal pain (14 percent) and sedation (13 percent). Syncope occurred in approximately 1 percent of ...
... attempts and suicides) occurred in 2% of all patients during treatment or during follow-up after treatment cessation. PEGINTRON induced fatigue or headache in approximately two-thirds of patients, with fever or rigors in approximately half of the patients. The severity of some of these systemic symptoms ...
... The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 ...
... 36%, 49%; vomiting 20%, 29%; anorexia 19%, 27%; headache 19%, 23%; constipation 18%, 22%; with the ... 1%, 1%; vomiting <1%, 2%; anorexia 1%, 1%; headache 2%, 4%; constipation 1%, 0%; convulsions 3%, 3%; ... were: nausea 10%, 53%; vomiting 6%, 42%; headache 6%, 41%; fatigue 4%, 34%; constipation 1%, 33%; ...
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
... sufferers and is a type of migraine in which the headache is preceded by symptoms such as visual ... Phase II trial, which was conducted at the Danish headache Center at Copenhagen's Glostrup ... in the trial was Professor Jes Olesen, the Danish headache Center's Director and one of the world's ...... presented in poster presentations at the European headache and Migraine Trust International Congress 2008 in ... was headache response, defined as a reduction in headache severity from moderate to severe at baseline to mild or no headache at two hours after initiation of infusion of ...
... 50th Annual Scientific Meeting of the American headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead ... in the following secondary endpoints: sustained headache response, absence of nausea or vomiting, absence ...
... therapy. He is a member of the American headache Society, The International headache Society and The National headache Foundation. Dr. Goldstein is a Board ...
... loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of the American headache Society, which being held at the Marriott ... Loxapine, a Dopamine Antagonist, Reduces headache Pain in Patients Having an Acute Migraine ...
... of neurology and director of the Jefferson headache Center at Thomas Jefferson University and an ... are undiagnosed. According to the International headache Society's diagnostic criteria, migraine is ... only be used where a clear diagnosis of migraine headache has been established. Treximet may cause an ...
... onset of a migraine and were treated once their headache was considered to be of moderate or severe ... in the placebo dose group. Patients rated their headache pain using the International Headache Society ... Migraine Headaches According to the National headache Foundation, approximately 13 million people in ...
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
... significant improvement on headache pain response at two hours post-dose compared to ... at three and four hours post-dose, sustained headache response at 24 hours, functional disability and a ... four hours post-dose that included measures of headache severity, nausea, vomiting, photophobia, ...... The primary efficacy endpoint for the trial is headache pain relief at two hours post-dose. ... and sustained pain free at 24 hours, and headache recurrence and relapse. Additional measures ... in the U.S. suffer from migraines. In addition to headache pain, migraine attacks are frequently accompanied ...
... 2 hours post-dose, using the standard 4-point rating scale (International headache Society). Secondary efficacy endpoints for the trial include pain relief ... About Acute Migraine Headaches According to the National headache Foundation, approximately 13 million people in the United States have been ...
... anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... of patients, with most mild to moderate in severity. The most common were headache (34 percent), contusion (32 percent), and fatigue (31 percent). ... General Safety -- In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction, occurring in 35 ...
... anemia (29%), edema (23%), headache, paresthesia and dysesthesia and headache (each 22%), dyspnea (21%), cough and insomnia (each 20%), rash (18%), ... pneumonia (16% vs 11%), dizziness (16% vs 11%), dyspnea (15% vs 13%), headache (14% vs 10%), pain in extremity (14% vs 9%), abdominal pain (14% vs 7%), ...
... (>10%) were rash (33%), pruritus (29%), nausea (31%), fatigue (28%), headache (31%), constipation (21%), diarrhea (22%) and vomiting (21%). The most ... (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased ...
... adverse events seen with Focalin XR were dyspepsia, decreased appetite, headache and anxiety in pediatric studies; and dry mouth, dyspepsia, feeling jittery, dizziness, headache and anxiety in adult studies. Focalin XR is contraindicated in patients ...
Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
... BOSTON, June 26 /PRNewswire-USNewswire/ -- headache specialists meet today in Boston for the 50th annual meeting of the American Headache Society. Learn more about headache and face pain developments of the last 50 years -- including the top five ...... ACTEMRA arm of the AMBITION trial were upper respiratory tract infections, headache and nasopharyngitis. About RADIATE Study The RADIATE (RheumAtoiD ... clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were ...
... were upper respiratory tract infections, nasopharyngitis, hypertension, headache and an increase in transaminases. "At one year, the results from the ... clinical studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. Increases in liver function tests (ALT and AST) were ...
... As reported last October, tezampanel met its primary endpoint of headache pain relief in a double-blind, placebo-controlled, Phase IIb trial ... opportunities for tezampanel and NGX426 as treatments for migraine headache and other chronic pain and non-pain indications. This will be in addition ...
Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
... against placebo in the clinical trial. Using the IHS (International headache Society) 4-point rating scale, the primary efficacy endpoint was ... of 2008." About Acute Migraine Headaches According to the National headache Foundation, approximately 13 million people in the United States have been ...SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
... placebo group in the randomized phase were insomnia (8.5% vs 17.5%) and headache (7.4% vs 4.9%).(3,6) Launched in 1997, SEROQUEL has been prescribed to ... 2%), sedation (13% vs 7%), somnolence (12% vs 4%), dizziness (10% vs 4%), headache (7% vs 5%), and orthostatic hypotension (7% vs 5%). In long-term clinical ...Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
... were mild-to-moderate diarrhea (cethromycin 4.5%, Biaxin 4.1%), headache (cethromycin 2.4%, Biaxin 3.1%), nausea (cethromycin 4.5%, Biaxin 1.4%), ... (13/288) (12/291) (13/260) (12/257) (26/548) (24/548) headache 2.4% 3.1% 3.1% 6.2% 2.7% 4.6% ...... to be drug-related were application site reactions, nausea, headache and dizziness SP 792 * In a multi-center, double-blind, ... adverse events were application site reactions (27.2%), nausea (21.5%), headache (17.6%) and somnolence (12.6%) 24-Month, Open-Label Extension Trial in ...
Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
... patients taking APTIVUS/r are diarrhea, nausea, fever, vomiting, fatigue, headache and abdominal pain. The most common laboratory abnormalities are elevated ... with APTIVUS/r were diarrhea, nausea, fever, vomiting, fatigue, headache and abdominal pain. Please see full Prescribing Information (PI), ...... usually transient and mild to moderate in severity.(1,2) Treatment-related adverse events greater than 10 percent included somnolence (32 percent), headache (26 percent), fatigue (18 percent), upper abdominal pain (14 percent), and sedation (13 percent).(11) Small to modest changes in blood pressure, ...
... A dry, irritated eye with tears dripping from the corner Pain around the ear or jaw, ringing in the ears, sensitivity to noise headache Loss of taste or a decrease in saliva production Bell's palsy can affect anyone, at any age. The risk rises until about age 40 ...
... tolerated. The adverse events reported most frequently in the ACTEMRA arms of the studies were upper respiratory tract infection, nasopharyngitis, headache and hypertension. About the AMBITION Study AMBITION, a two-arm, randomized, double-blind, placebo-controlled study, was designed to ...
... the SF-36 health survey and for all sections of the EQ-5D questionnaire(6). The most commonly reported adverse events for tadalafil 40 mg were headache (42 percent for tadalafil 40 mg, versus 15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus 4 percent with placebo) and ...
... adverse events (reported frequency greater than or equal to 10% among lurasidone subjects) for lurasidone versus placebo were nausea (16% vs. 3%), headache (11.1% vs. 10%), constipation (11.1% vs. 5.6%), vomiting (11.1% vs. 5.6%), dyspepsia (11.1% vs. 3.3%), somnolence (11.1% vs. 3.3%), insomnia (10.0% ...
... with HZT-501 was well-tolerated. The most commonly reported adverse events in these two studies were dyspepsia, nausea, diarrhea, constipation, headache and upper respiratory tract infection. The majority were mild to moderate in severity. There were no significant differences in adverse event or ...
... moderate in severity. In clinical trials (N=535), the most common treatment-related adverse events with Lialda 2.4 g/day, 4.8 g/day and placebo were headache (5.6%, 3.4% and 0.6%, respectively) and flatulence (4%, 2.8% and 2.8%, respectively). Pancreatitis occurred in less than 1% of patients during ...
... were usually transient and mild or moderate in severity. Treatment-related adverse events greater than 10 percent included somnolence (32 percent), headache (26 percent), fatigue (18 percent), upper abdominal pain (14 percent) and sedation (13 percent). Syncope occurred in approximately 1 percent of ...
Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
... (n=640) and more frequently than with placebo with concomitant methotrexate (n=324) were upper respiratory tract infection (6% CIMZIA, 2% placebo), headache (5% CIMZIA, 4% placebo), hypertension (5% CIMZIA, 2% placebo), nasopharyngitis (5% CIMZIA, 1% placebo), back pain (4% CIMZIA, 1% placebo), pyrexia ...Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
... aura. Two dose levels of AZ-104 are being evaluated in the clinical trial, 1.25 mg and 2.5 mg. The primary efficacy endpoint for the trial is headache pain relief at 2 hours post-dose, using the standard IHS 4-point rating scale. Secondary efficacy endpoints for the trial include pain relief and ...Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
... study. The most common adverse events reported for the full-dose, mid-dose and placebo group were tingling (23%, 16%, 3%), dry mouth (18%, 13%, 0%), headache (16%, 15%, 13%), and constipation (15%, 7%, 8%). The completion rate for the study overall was 70 percent. "The weight loss seen across our ...... attempts and suicides) occurred in 2% of all patients during treatment or during follow-up after treatment cessation. PEGINTRON induced fatigue or headache in approximately two-thirds of patients, with fever or rigors in approximately half of the patients. The severity of some of these systemic symptoms ...
... The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 ...
Other ContentsforebrainforebrainforebrainfossilfossilfossilfossilfossilfrondframeshiftfungifungifungifungifungifungifructosefructosefructosefructosefructosefusionfusionfusionfusionfusionfusionfusionfusionfusionOther TagsAnaerobicAnchorAnneal
(Date:12/3/2009)...of plant and animal species can be likened to empt...net full of potential medicines into the trash, or...gers. , But the decline of species and their hab...arch now suggests it may also put you at greater r...destruction and biodiversity loss,"driven by the r...
(Date:12/3/2009)...s message: , , Preliminary Press Conference T... Academy of Sciences museum, Attention PIOs: Sen...ay dinner registration deadline 10 December, Ne...egistration Form pre-registration deadline THIS MO...tant information regarding visas for international...
(Date:12/3/2009)...N.M. Most scientists believe that staph infection...ach other to emit toxins. The signaling process is...be present to start the process. , But the Jeff ...y first stage of staph infection, when bacteria sw... a single cell and that this individual process ca...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 1Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 2Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 3Experts Outline Challenges to Translational Research in the United States at a Capitol Hill Briefing Emphasizing the Importance of Bringing Medical I 57486 4FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 1FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 2FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 3FLAVORx Helps Families Fight Pandemic H1N1 Influenza Virus By Making Antiviral Medicine Taste Better 14118 4J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 1J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 2J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 3J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 4J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 5J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 6J D Power and Associates Reports 3A Among Pharmacy Customers Satisfaction is Equally as High for the Privately Insured and for Those With Public Pri 57477 7(Date:12/4/2009)...ase Western Reserve University researchers, from t...iscovered two new metabolic pathways by which prod..., known as 4-hydroxyacids, are metabolized. The pa...omics and mass isotopomer analysis. The findings s...ug of abuse gamma-hydroxybutyrate, also known as "...
(Date:12/4/2009)... Dental tourism is a phenome...or an alternative to the high price of dental work...search for lower priced dental care, people have f...e as a dental tourist destination. , ...g in business for more than 6 years, Mexican Denta...
(Date:12/4/2009)...e a response to pressure from federal regulators t... , FRIDAY, Dec. 4 (HealthDay News) -- The mak...iday presented federal regulators with plans to cu...maceutical companies have been under pressure from...nd a way to stop the hundreds of fatal overdoses t...
(Date:12/4/2009)...earch and surveillance urged for at-risk patient g...) -- Some childhood cancers, particularly Ewing sa...e risk of late recurrence, U.S. researchers have f...,795 five-year survivors of the most common pediat...cer Survivor Study. , The researchers found tha...
(Date:12/4/2009)...times more smoke inhaled through hookah, research ...) -- Water pipes are no safer than cigarettes for ... found that people who smoke tobacco with a water ...ts them at risk for heart disease and nicotine add...d 18 to 50, who smoked tobacco using a water pipe ...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Water Pipes No Safer Than Cigarettes 2[0] Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week'[0] Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor [0] Makers of Powerful Painkillers Present Safety Plans [0] Certain Childhood Cancers More Likely to Recur[0] Water Pipes No Safer Than Cigarettes
AnaerobeAnabaenaAnaerobicAnagenesisAnaphaseAndrogensAnchorAneuploidAneuploidyAnlageAngiospermAnimaliaAnnealAnnulus
Other Tagspump 2pump 3pump 4pump 5pump 6sell 2sell 3sell 4sell 5sell 6sell 7sell 8sell 9refuse 2refuse 3refuse 4burning 2burning 3raw 2raw 3mediates 2| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |